- New study finds contaminants in many generic drugs may have ...🔍
- Drug Policy🔍
- Generic Drugs🔍
- Carcinogens Have Infiltrated the Generic Drug Supply in the U.S.🔍
- First Generic Drug Approvals🔍
- Drugmakers are abandoning cheap generics🔍
- Cancer Drug Price and Novelty in Mechanism of Action🔍
- Oncology drug pricing🔍
Generic drugs in oncology
New study finds contaminants in many generic drugs may have ...
... cancer, according to a new UBC study.
Drug Policy: Generic Drugs - EmblemHealth
I. PURPOSE. To define and describe the accepted indications for generic drugs usage in the treatment of cancer. Generic drug list is also being used to ...
Generic Drugs - Friends of Cancer Research
Generic drugs compete with the original drug, significantly reducing both the cost of the originator drug and the generic drug.
Carcinogens Have Infiltrated the Generic Drug Supply in the U.S.
It's known to cause cancer in animals and is classified as a probable carcinogen in humans—it's most toxic to the liver. A single dose of less ...
First Generic Drug Approvals - FDA
First-Time Generic Drug Approvals 2024* ; 50, 219002, Trametinib Tablets, 0.5 mg and 2 mg, Novugen Oncology Sdn. Bhd. Mekinist (Trametinib) Tablets ; 49, 216935 ...
Drugmakers are abandoning cheap generics, and now U.S. cancer ...
... generic cisplatin and carboplatin, two cheap drugs used to treat as many as 500,000 new cancer cases every year. Seven months later, doctors ...
Cancer Drug Price and Novelty in Mechanism of Action
Results There were 224 cancer drug approvals across 119 individual drugs, with a median annual cost of $196 000 (IQR, $170 000-$277 000). Gene ...
Oncology drug pricing: potential Medicare savings on cancer ...
Prescription drug costs are a challenge for patients with cancer. The Mark Cuban Cost Plus Drug Company (MCCPDC) launched in 2022, ...
Effectiveness of Generic vs Brand Name Chemotherapy Drugs
Effectiveness of Generic vs Brand Name Chemotherapy Drugs ... Generic medications contain the same active ingredient as the respective brand name ...
Generic Cancer Drugs May Be Unsafe in Developing Countries
After analyzing this data, they found that generic oncology drugs are typically safe in countries with regulatory organizations similar to the ...
Safety Concerns for Generic Oncology Drugs in Developing Countries
Generic cancer drugs are generally safe in countries with rigorous regulatory programs similar to the FDA in the United States.
Analysis of the evolution of the price of oncology drugs after the loss ...
Evolution of the LPs notified after the appearance of generic medicines ; Vinorelbine, Not available, −37% ; Capecitabine, 14/12/2013, −39% ...
Priced Out: Generic Therapy Price Competition and Drug Shortages
In oncology, branded products like Paraplatin and Platinol have long been off-patent allowing for numerous cisplatin and carboplatin generics.
Shortages of generic cancer medicines are harming patients. So ...
A persistent problem of re-occurring shortages across a wide range of generics is damaging patient outcomes, adding to the workloads of hospital pharmacists.
Estimated generic prices of cancer medicines deemed cost ...
The aim of this study was to estimate lowest possible treatment costs for four novel cancer drugs, hypothesising that generic manufacturing could significantly ...
Prescription drugs (outpatient) - Your Medicare Coverage
Oral cancer drugs: Medicare covers some cancer drugs you take by mouth if the same drug is available in injectable form, or it's a prodrug of the injectable ...
Exploring the Efficacy of Generic Drugs in Treating Cancer
We introduce a natural language processing pipeline to automate the identification of relevant studies and facilitate the extraction of therapeutic ...
Cancer Drug Shortage: Causes, Trends, and Implications for Clinical ...
Primary causes of the cancer drug shortage include manufacturing issues, supply chain disruptions, and regulatory delays.
Pathways for non-manufacturers to drive generic drug repurposing ...
In oncology, many generic drugs approved for non-cancer uses have been tested as cancer treatments; published preclinical and early clinical ...
Barriers in access to oncology drugs — a global crisis - Nature
Only a minority of Indian oncologists (3%) reported universal access to essential medicines, and the risk of substantial OOP expenditure for ...